 AUSTIN, Texas, March 09, 2021 GLOBE NEWSWIRE -- Lumos Pharma, Inc. NASDAQ:LUMO, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2020 and provided an update on clinical activities and financial guidance for 2021. 